Hospital Management
RSSArticles
-
Smothered Newborn Shows Patient Safety, Liability Risks
A tragic newborn death illustrates the patient safety risks posed by simply leaving an infant to sleep in the arms of its mother, risks that are increasing with the emphasis on more physical contact between the mother and child.
-
Study: Readmissions More Common After Observation Stays
Patients often are readmitted to the hospital after an observation stay, according to recent research which suggests hospitals may want to target this population.
-
Program Offers Psychological First Aid, Support to HCWs Following Traumatic Events
When an adverse outcome occurs, support rightfully flows to the affected patients and families. However, the clinicians involved with such cases often suffer, too, and the resulting stress and anguish can lead to decreased productivity, time away from work, depression, and other serious mental health effects.
-
Expert: Health Systems Should Emphasize Value-based Care Management
Since health insurers first developed case management programs in the 1980s, the marketplace for case management has evolved and changed across the continuum of care, with one possible exception: hospital settings.
-
Recent CMS Payment Model Cancellations Could Affect Case Management
Case management programs could see some effects from the recent canceling of advanced care coordination through episode payment by the Centers for Medicare & Medicaid Services.
-
Case Management Program Cuts Heart Failure Readmissions in Half
A case management program targeted health improvements among congestive heart failure patients and succeeded in cutting readmission rates to half the national average.
-
Study: Trial Results for New Neurological Drugs Often Go Unpublished
Results of clinical trials for “stalled” neurological drugs — those which had at least one completed Phase III trial but failed to receive FDA approval — are heavily underreported, found a new study.
-
AllTrials Seeks Transparency in Big Pharma Studies
The AllTrials campaign, striving to achieve full disclosure of all results in clinical trials, recently conducted an audit of the transparency policies of pharmaceutical companies, finding them open enough on the surface — but beset with devils in the details.
-
Broad Consent Issues raised by SACHRP and Others
With broad consent, patients would have an easy and speedy opportunity to opt out of future research uses of their biospecimens. But if they didn’t opt out — and most people probably would agree to the research use of their specimens — then scientific progress could proceed without the consent roadblock.
-
FDA Lowers the Boom on Stem Cell Clinics
The FDA recently cracked down on two stem cell clinics for questionable research practices, including one clinic that was using smallpox vaccine as part of a treatment protocol.